NVO

Novo-Nordisk A/S
D

NVO

41.180
USD
2.67
(6.92%)
Market Closed
Volume
928,744
EPS
22
Div Yield
4.38
P/E
11
Market Cap
182,647,803,967
OverviewNews
News
ArincenArincen
AAPL
ORCL
MSFT
NVDA
AMZN
XAUUSD
XAGUSD
EURUSDEURUSD
2 months ago

Market Roundup: What Happened Yesterday and What Awaits Us Today (February 10)

ArincenArincen
MSFT
NVDA
PLTR
IT
DVA
TER
PEP
MRK
2 months ago

Market Roundup: What Happened Yesterday and What Awaits Us Today (February 4)

ArincenArincen
NVO
LLY
EURUSDEURUSD
USDJPYUSDJPY
GBPUSDGBPUSD
USDCADUSDCAD
NZDUSDNZDUSD
USDCHFUSDCHF
4 months ago

Novo Nordisk Shares Soar as FDA Clears First Weight-Loss Pill

ArincenArincen
NVO
LLY
DKKTRYDKKTRY
HKDDKKHKDDKK
GBPDKKGBPDKK
DKKZARDKKZAR
DKKXDRDKKXDR
DKKUSDDKKUSD
7 months ago

Novo Nordisk Cuts 9,000 Jobs as Obesity Drug Battle Intensifies

ArincenArincen
SAP
NVO
ASML
M
R
NVDA
MSFT
AAPL
9 months ago

Europe’s Biggest Companies Fall Further Behind US Rivals

More

Title: Novo/Nordisk A/S

Sector: Healthcare
Industry: Drug Manufacturers - General
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android
Social Network
The NetworkSignals NetworkIdeas NetworkBest TradersUser Reviews for Brokers
Company
Contact usAbout usTerms Of UsePrivacy PolicyCookies PolicyDisclaimerHouse rulesHelp Centeradvertising with ArincenOur servicesReferral programDownload Mobile App
Products
Risk CalculatorPip CalculatorAdvance Chart
Markets
Exchange RatesCommodities RatesCryptocurrencies RatesIndices RatesUS Stocks Rates

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.